Becton, Dickinson and (BDX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $3.23
- Estimate
- $3.14
- Surprise
- +2.9%
- Revenue (period 2026-06-30)
- $4.98B
- Score at report (before → after)
- 5.4 → 5.0/10
Revenue source: xbrl.
How the report landed
Becton, Dickinson and (BDX) beat the $3.14 estimate with adjusted EPS of $3.23 — a modest 2.9% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.4/10) to Hold at 5.0/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates BDX Sell at 4.9/10.
4 of the last 4 quarters beat the estimate; this quarter's +2.9% surprise compares with a +3.1% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Supplier: sole sourced
- Analyst target reached - limited upside remaining
- Near 52-week high (2.0% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $196.39
- Stop
- $188.15
The stock trades at 45.7× trailing but 14.8× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 74 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-27 — shown for context, not personalized investment advice.
BDX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $53.49B
- P/E (fwd)
- 14.8
- P/E (ttm)
- 45.7
- 52-week range
- $127.59–$200.47
- Off 52-week high
- 2.0%
- RSI (14)
- 74
- Volume vs avg
- 1.08×
- Score today
- 4.9/10